Ernexa Therapeutics (ERNA) Competitors

$11.99 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$11.80 -0.19 (-1.58%)

As of 05/22/2026 07:48 PM Eastern

ERNA vs. BYSI, HYPD, INKT, SCLX, and ESLA

Should you buy Ernexa Therapeutics stock or one of its competitors? MarketBeat compares Ernexa Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ernexa Therapeutics include BeyondSpring (BYSI), Hyperion DeFi (HYPD), MiNK Therapeutics (INKT), Scilex (SCLX), and Estrella Immunopharma (ESLA). These companies are all part of the "pharmaceutical products" industry.

How does Ernexa Therapeutics compare to BeyondSpring?

Ernexa Therapeutics (NASDAQ:ERNA) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

BeyondSpring's return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-263.74%	-151.16%
BeyondSpring	N/A	N/A	-14.00%

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by company insiders. Comparatively, 29.3% of BeyondSpring shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ernexa Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

Ernexa Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 150.21%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Ernexa Therapeutics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BeyondSpring has higher revenue and earnings than Ernexa Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	24.19	-$14.08M	-$26.20	N/A
BeyondSpring	$1.75M	36.89	-$1.01M	-$0.14	N/A

In the previous week, BeyondSpring had 1 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 2 mentions for BeyondSpring and 1 mentions for Ernexa Therapeutics. BeyondSpring's average media sentiment score of 0.72 beat Ernexa Therapeutics' score of 0.50 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ernexa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeyondSpring	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BeyondSpring beats Ernexa Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Hyperion DeFi?

Ernexa Therapeutics (NASDAQ:ERNA) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Ernexa Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 150.21%. Hyperion DeFi has a consensus price target of $5.88, indicating a potential upside of 62.29%. Given Ernexa Therapeutics' higher possible upside, equities research analysts clearly believe Ernexa Therapeutics is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Hyperion DeFi's return on equity of -91.59% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-263.74%	-151.16%
Hyperion DeFi	N/A	-91.59%	-73.08%

Ernexa Therapeutics has higher earnings, but lower revenue than Hyperion DeFi. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	24.19	-$14.08M	-$26.20	N/A
Hyperion DeFi	$810K	67.75	-$45.31M	-$9.95	N/A

Ernexa Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. Comparatively, Hyperion DeFi has a beta of 2.57, indicating that its stock price is 157% more volatile than the broader market.

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by insiders. Comparatively, 7.5% of Hyperion DeFi shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Ernexa Therapeutics and Ernexa Therapeutics both had 1 articles in the media. Hyperion DeFi's average media sentiment score of 0.54 beat Ernexa Therapeutics' score of 0.50 indicating that Hyperion DeFi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ernexa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperion DeFi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Hyperion DeFi beats Ernexa Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Ernexa Therapeutics compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

MiNK Therapeutics presently has a consensus target price of $35.00, indicating a potential upside of 221.99%. Ernexa Therapeutics has a consensus target price of $30.00, indicating a potential upside of 150.21%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe MiNK Therapeutics is more favorable than Ernexa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MiNK Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market.

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 22.5% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, MiNK Therapeutics had 9 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 10 mentions for MiNK Therapeutics and 1 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.50 beat MiNK Therapeutics' score of 0.10 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ernexa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiNK Therapeutics' return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
Ernexa Therapeutics	N/A	-263.74%	-151.16%

MiNK Therapeutics has higher earnings, but lower revenue than Ernexa Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
Ernexa Therapeutics	$580K	24.19	-$14.08M	-$26.20	N/A

Summary

MiNK Therapeutics beats Ernexa Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Scilex?

Scilex (NASDAQ:SCLX) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Ernexa Therapeutics has lower revenue, but higher earnings than Scilex. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	1.71	-$358.73M	-$40.47	N/A
Ernexa Therapeutics	$580K	24.19	-$14.08M	-$26.20	N/A

Ernexa Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 150.21%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

69.7% of Scilex shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 4.1% of Scilex shares are held by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Scilex had 4 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 5 mentions for Scilex and 1 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.50 beat Scilex's score of -0.04 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scilex	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ernexa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scilex has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market.

Ernexa Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,110.17%	N/A	-143.55%
Ernexa Therapeutics	N/A	-263.74%	-151.16%

Summary

Ernexa Therapeutics beats Scilex on 10 of the 16 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Estrella Immunopharma?

Estrella Immunopharma (NASDAQ:ESLA) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

In the previous week, Estrella Immunopharma and Estrella Immunopharma both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 3.00 beat Ernexa Therapeutics' score of 0.50 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Estrella Immunopharma	Very Positive
Ernexa Therapeutics	Positive

Estrella Immunopharma presently has a consensus price target of $8.00, indicating a potential upside of 589.66%. Ernexa Therapeutics has a consensus price target of $30.00, indicating a potential upside of 150.21%. Given Estrella Immunopharma's higher possible upside, equities research analysts clearly believe Estrella Immunopharma is more favorable than Ernexa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

0.4% of Estrella Immunopharma shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 55.1% of Estrella Immunopharma shares are held by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Estrella Immunopharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market.

Estrella Immunopharma's return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
Ernexa Therapeutics	N/A	-263.74%	-151.16%

Estrella Immunopharma has higher earnings, but lower revenue than Ernexa Therapeutics. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
Ernexa Therapeutics	$580K	24.19	-$14.08M	-$26.20	N/A

Summary

Estrella Immunopharma beats Ernexa Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Ernexa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ERNA vs. The Competition

Export

Metric	Ernexa Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.98M	$3.04B	$6.46B	$12.34B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	-0.46	17.79	21.22	25.66
Price / Sales	24.19	336.21	562.28	86.31
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	2.04	5.86	10.31	7.14
Net Income	-$14.08M	$74.99M	$3.57B	$335.98M
7 Day Performance	4.72%	3.11%	6.43%	4.15%
1 Month Performance	150.18%	-3.05%	3.57%	2.54%
1 Year Performance	-85.98%	34.38%	34.07%	35.06%

Ernexa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ERNA Ernexa Therapeutics	3.1413 of 5 stars	$11.99 flat	$30.00 +150.2%	-86.0%	$13.98M	$580K	N/A	10	Earnings Report
BYSI BeyondSpring	0.3394 of 5 stars	$1.44 +11.6%	N/A	-9.2%	$53.04M	$1.75M	N/A	80
HYPD Hyperion DeFi	3.0253 of 5 stars	$3.78 +10.2%	$5.88 +55.4%	+104.5%	$52.07M	$810K	N/A	40	Gap Up
INKT MiNK Therapeutics	2.6064 of 5 stars	$10.72 +3.6%	$35.00 +226.5%	+53.2%	$51.56M	N/A	N/A	30	Gap Down
SCLX Scilex	0.3391 of 5 stars	$6.01 +0.5%	N/A	+34.3%	$50.78M	$30.25M	N/A	80	Earnings Report Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ERNA) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ernexa Therapeutics (ERNA) Competitors

ERNA vs. BYSI, HYPD, INKT, SCLX, and ESLA

How does Ernexa Therapeutics compare to BeyondSpring?

Summary

How does Ernexa Therapeutics compare to Hyperion DeFi?

Summary

How does Ernexa Therapeutics compare to MiNK Therapeutics?

Summary

How does Ernexa Therapeutics compare to Scilex?

Summary

How does Ernexa Therapeutics compare to Estrella Immunopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERNA vs. The Competition

Ernexa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ernexa Therapeutics (ERNA) Competitors

ERNA vs. BYSI, HYPD, INKT, SCLX, and ESLA

How does Ernexa Therapeutics compare to BeyondSpring?

Is ERNA or BYSI more profitable?

Do institutionals and insiders believe in ERNA or BYSI?

Which has more risk & volatility, ERNA or BYSI?

Do analysts recommend ERNA or BYSI?

Which has preferable valuation & earnings, ERNA or BYSI?

Does the media prefer ERNA or BYSI?

Summary

How does Ernexa Therapeutics compare to Hyperion DeFi?

Do analysts recommend ERNA or HYPD?

Is ERNA or HYPD more profitable?

Which has stronger earnings and valuation, ERNA or HYPD?

Which has more volatility & risk, ERNA or HYPD?

Do institutionals & insiders believe in ERNA or HYPD?

Does the media prefer ERNA or HYPD?

Summary

How does Ernexa Therapeutics compare to MiNK Therapeutics?

Do analysts rate INKT or ERNA?

Which has more volatility & risk, INKT or ERNA?

Do insiders & institutionals have more ownership in INKT or ERNA?

Does the media favor INKT or ERNA?

Is INKT or ERNA more profitable?

Which has higher earnings and valuation, INKT or ERNA?

Summary

How does Ernexa Therapeutics compare to Scilex?

Which has stronger valuation & earnings, SCLX or ERNA?

Do analysts prefer SCLX or ERNA?

Do insiders and institutionals have more ownership in SCLX or ERNA?

Does the media refer more to SCLX or ERNA?

Which has more risk & volatility, SCLX or ERNA?

Is SCLX or ERNA more profitable?

Summary

How does Ernexa Therapeutics compare to Estrella Immunopharma?

Does the media favor ESLA or ERNA?

Do analysts recommend ESLA or ERNA?

Do insiders & institutionals hold more shares of ESLA or ERNA?

Which has more risk & volatility, ESLA or ERNA?

Is ESLA or ERNA more profitable?

Which has better valuation and earnings, ESLA or ERNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERNA vs. The Competition

Ernexa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools